Skip to main content

Anturol FDA Approval History

FDA Approved: Yes (Discontinued) (First approved December 7, 2011)
Brand name: Anturol
Generic name: oxybutynin
Dosage form: Gel
Company: Antares Pharma, Inc.
Treatment for: Overactive Bladder

Marketing Status: Discontinued

Anturol (oxybutynin) is an anticholinergic transdermal gel formulation indicated for the management of overactive bladder.

Development timeline for Anturol

DateArticle
Dec  8, 2011Approval Anturol Approved by FDA for the Treatment of Overactive Bladder
Apr  8, 2011Antares Pharma Announces FDA Acceptance of Anturol NDA for Filing
Dec 22, 2010Antares Pharma Announces Filing of New Drug Application for Anturol for Overactive Bladder

See also

Anturol (oxybutynin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer